14.15
0.04 (0.28%)
| Previous Close | 14.11 |
| Open | 14.10 |
| Volume | 10,615 |
| Avg. Volume (3M) | 35,245 |
| Market Cap | 2,555,510,272 |
| Price / Earnings (TTM) | 5.34 |
| Price / Earnings (Forward) | 20.53 |
| Price / Sales | 4.91 |
| Price / Book | 2.14 |
| 52 Weeks Range | |
| Earnings Date | 5 Mar 2026 |
| Profit Margin | 5.99% |
| Operating Margin (TTM) | -4.99% |
| Diluted EPS (TTM) | 0.200 |
| Quarterly Revenue Growth (YOY) | 6.40% |
| Quarterly Earnings Growth (YOY) | -84.70% |
| Total Debt/Equity (MRQ) | 11.64% |
| Current Ratio (MRQ) | 2.83 |
| Operating Cash Flow (TTM) | -46.98 M |
| Levered Free Cash Flow (TTM) | -50.75 M |
| Return on Assets (TTM) | -2.14% |
| Return on Equity (TTM) | 5.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | HUTCHMED (China) Limited | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.38 |
|
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.12% |
| % Held by Institutions | 3.87% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Crossmark Global Holdings, Inc. | 31 Dec 2025 | 52,476 |
| Neos Investment Management Llc | 31 Dec 2025 | 49,573 |
| Dekabank Deutsche Girozentrale | 31 Dec 2025 | 41,362 |
| 52 Weeks Range | ||
| Median | 20.00 (41.34%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 10 Mar 2026 | 20.00 (41.34%) | Buy | 13.89 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Feb 2026 | Announcement | HUTCHMED to Announce 2025 Final Results |
| 13 Jan 2026 | Announcement | HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |